Skip to main content
Clinical Trials/NCT03492424
NCT03492424
Recruiting
N/A

Ablative Therapy in the Management of Prostate Cancer

Weill Medical College of Cornell University1 site in 1 country200 target enrollmentJanuary 2, 2018
ConditionsProstate Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Weill Medical College of Cornell University
Enrollment
200
Locations
1
Primary Endpoint
Prostate biopsy Gleason grade
Status
Recruiting
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy.

Detailed Description

Through the use of a pro- and retrospective registry, the investigators will collect information on patient characteristics including age, co-morbidities, imaging and biopsy information, and prior treatments. Information on treatment details will also be captured, including treatment time, anesthesia delivered, and length of stay, when applicable. Oncologic outcomes including PSA, post-treatment biopsy and imaging data, need for re-treatment, and survival outcomes will also be captured. Safety outcomes will be captured using the Clavien-Dindo classification scale, and additional specific GU complications will be recorded, which include urinary retention, urethral stricture, recto-urethral fistula, osteomyelitis, and urinary tract infection. Finally, the investigators will capture functional outcomes using health related quality of life questionnaires including the EPIC questionnaire, IIEF-5, MSHQ-EjD, and IPSS.

Registry
clinicaltrials.gov
Start Date
January 2, 2018
End Date
September 2, 2039
Last Updated
4 months ago
Study Type
Observational
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \>18 years of age
  • Undergoing focal therapy for primary or salvage treatment of prostate cancer, or
  • Have received prior focal therapy

Exclusion Criteria

  • Clinically-evident metastatic disease
  • Unable to fill out an English-language questionnaire

Outcomes

Primary Outcomes

Prostate biopsy Gleason grade

Time Frame: 12 months

Will be obtained through patient biopsy pathology results

Secondary Outcomes

  • Patient characteristics/demographics(12 months)
  • MRI PI-RAD grade(12 months)
  • Lab results - PSA level(12 months)
  • Patient-reported quality of life: MSHQ-EjD(12 months)
  • Patient-reported quality of life: EPIC-26(12 months)
  • Patient-reported quality of life: IIEF-5(12 months)
  • Patient-reported quality of life: IPSS(12 months)

Study Sites (1)

Loading locations...

Similar Trials